HYPD
NASDAQ · Pharmaceuticals
Hyperion Defi Inc
$2.49
-0.07 (-2.73%)
Financial Highlights (FY 2026)
Revenue
2.58M
Net Income
-143,650,775
Gross Margin
62.7%
Profit Margin
-5,570.6%
Rev Growth
—
D/E Ratio
0.19
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 62.7% | -6,749.0% | 34.6% | 34.6% |
| Operating Margin | -5,456.5% | -76,498.8% | 35.0% | 36.3% |
| Profit Margin | -5,570.6% | -82,538.4% | 29.2% | 24.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.58M | 4.90M | 5.01M | 5.20M |
| Gross Profit | 1.62M | -330,594,412 | 1.73M | 1.80M |
| Operating Income | -140,724,732 | -3,747,220,824 | 1.75M | 1.89M |
| Net Income | -143,650,775 | -3,832,248,999 | 1.46M | 1.25M |
| Gross Margin | 62.7% | -6,749.0% | 34.6% | 34.6% |
| Operating Margin | -5,456.5% | -76,498.8% | 35.0% | 36.3% |
| Profit Margin | -5,570.6% | -82,538.4% | 29.2% | 24.0% |
| Rev Growth | — | -84.0% | +22.0% | +7.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 3.15M | 15.59M | 11.29M | 13.39M |
| Total Equity | 16.59M | 9.82M | 25.06M | 25.22M |
| D/E Ratio | 0.19 | 1.59 | 0.45 | 0.53 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -140,667,528 | -3,873,168,857 | 1.99M | 2.29M |
| Free Cash Flow | — | — | 1.60M | 1.59M |